Dadonville, France

Daniel Lagin

This inventor holds 1 USPTO granted patent. Top assignee: Riker Laboratories Inc.. Active years: 1997.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Daniel Lagin

Introduction

Daniel Lagin is an accomplished inventor based in Dadonville, France. He has made significant contributions to the field of chemistry, particularly in the development of novel compounds. His work focuses on the preparation of specific chemical structures that have potential applications in various industries.

Latest Patents

Lagin holds a patent for a process related to 1H-imidazo[4,5-C]quinolines. This patent details a method for the preparation of 1-substituted, 4-substituted-1H-imidazo-[4,5-c]quinolines, which are intermediates in the synthesis of such compounds. The patent represents a significant advancement in the field, showcasing Lagin's expertise and innovative approach to chemical processes. He has 1 patent to his name.

Career Highlights

Daniel Lagin is currently employed at Riker Laboratories Inc., where he continues to push the boundaries of chemical research. His work at the company has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to innovation.

Collaborations

One of Lagin's notable collaborators is Jean-Denis André. Their partnership exemplifies the importance of teamwork in the pursuit of scientific advancements.

Conclusion

Daniel Lagin's innovative work in the field of chemistry, particularly through his patent on 1H-imidazo[4,5-C]quinolines, highlights his role as a significant contributor to the scientific community. His career at Riker Laboratories Inc. and collaborations with other experts further underscore his commitment to advancing chemical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…